Beyond the Headlines Into the Heart of the Matter
Image Credit: Adobe Stock Images/Wladimir1804.com Key Takeaways MA enrollment among full-benefit dual-eligible beneficiaries is rising, reaching nearly 50% by 2022. FIDE-SNP enrollees have greater health and support needs than those in other MA plan types. FIDE-SNP enrollees are more likely to live in less disadvantaged areas, pointing to access disparities.…
In a video interview with Pharma Commerce, Maggie McCullough, PolicyMap’s CEO, highlights how geospatial mapping can play a critical role in identifying and addressing pharmacy deserts—areas where access to pharmacies is limited or nonexistent. With an estimated 17.7% of the US population affected, the issue is increasingly urgent, particularly as…
In a video interview with Pharma Commerce, Maggie McCullough, PolicyMap’s CEO, highlights how geospatial mapping can play a critical role in identifying and addressing pharmacy deserts—areas where access to pharmacies is limited or nonexistent. With an estimated 17.7% of the US population affected, the issue is increasingly urgent, particularly as…
Image Credit: Adobe Stock Images/Hugnaka.com Key Takeaways BioNTech and Bristol Myers Squibb have entered a major global collaboration to co-develop and co-commercialize BNT327, a bispecific antibody for solid tumors, with $1.5B upfront, $2 billion total in non-contingent anniversary payments through 2028, and up to $7.6B in milestone payments. BNT327 is…
In a video interview with Pharma Commerce, Scott Tillman, Logility’s senior vice president of innovation, addresses the gap between high interest in generative AI (GenAI) and its relatively low adoption in supply chain-specific applications, as highlighted in Logility’s Supply Chain Horizons 2025 Market Report. He identified several key reasons for…
Image Credit: Adobe Stock Images/Somneuk.com Key Takeaways Tariffs could spike drug costs: Proposed 25% tariffs on pharmaceuticals may raise US drug prices by up to 12.9% and cost the industry an estimated $51 billion annually. Supply chain disruption is growing: Pharma and medtech sectors face significant supply chain strain, including…
In a video interview with Pharma Commerce, Scott Tillman, Logility’s senior vice president of innovation, addresses the gap between high interest in generative AI (GenAI) and its relatively low adoption in supply chain-specific applications, as highlighted in Logility’s Supply Chain Horizons 2025 Market Report. He identified several key reasons for…
Key Takeaways Exceptional CX significantly boosts engagement with healthcare professionals and consumers, leading to increased prescriptions, better market penetration, and improved health outcomes. Pharma companies are leveraging AI-driven omnichannel platforms to unify customer data, personalize interactions, and meet rising expectations across direct-to-consumer and direct-to-patient models. Unified platforms powered by AI…
In a video interview with Pharma Commerce, Scott Tillman, Logility’s senior vice president of innovation, addresses the gap between high interest in generative AI (GenAI) and its relatively low adoption in supply chain-specific applications, as highlighted in Logility’s Supply Chain Horizons 2025 Market Report. He identified several key reasons for…
May 28th 2025 Article When a South Korean patient needed a life-changing gene therapy, Marken orchestrated an international distribution strategy under the strictest regulatory and temperature specifications. With precise temperature-control required at -80°C with dry ice, Marken’s teams navigated weekend scheduling, specialized package handling and final-mile complexities to ensure the…
When Coretta learned she had stage 4 non-small cell lung cancer, she was blindsided. She didn’t fit the profile. She didn’t see it coming. And she didn’t know what to do next. It’s a common experience in serious diagnoses—patients feel not just fear but paralysis. The problem? Coretta had never…
May 28th 2025 Article Tasked with the delivery of two ultra-sensitive gene therapies to Japan – treatments targeting vision loss that required continuous -80°C temperature control and dry ice replenishment throughout an 80-hour transit – Marken activated a customized, precision-driven supply chain strategy. Navigating one of the world’s most complex…
In this exclusive PC Podcast interview, Alice Valder Curran, partner at Hogan Lovells, explores: How recent executive orders—both under the Biden and Trump administrations—have reshaped the drug pricing landscape, and the legal challenges or uncertainties they present for pharmaceutical companies What life sciences companies should be doing now to proactively prepare for…
In a video interview with Pharma Commerce, Scott Tillman, Logility’s senior vice president of innovation, addresses the gap between high interest in generative AI (GenAI) and its relatively low adoption in supply chain-specific applications, as highlighted in Logility’s Supply Chain Horizons 2025 Market Report. He identified several key reasons for…
Image Credit: Adobe Stock Images/PostModernStudio.com Key Takeaways Full interchangeability approved: The FDA has granted full interchangeability to Hadlima for all Humira formulations, allowing pharmacist substitution without prescriber consultation (per state law). Expanded patient access: This designation may significantly reduce out-of-pocket costs and improve access to biologic therapies for patients across…
In a video interview with Pharma Commerce, Scott Tillman, Logility’s senior vice president of innovation, addresses the gap between high interest in generative AI (GenAI) and its relatively low adoption in supply chain-specific applications, as highlighted in Logility’s Supply Chain Horizons 2025 Market Report. He identified several key reasons for…
Image Credit: Adobe Stock Images/Feodora.com Main Takeaways The merger of Mercalis and PharmaCord, backed by Permira and Odyssey Investment Partners, forms Valeris—a platform aimed at streamlining how life sciences companies bring therapies to market through integrated patient support, data, and provider engagement tools. Valeris intends to transform the commercialization process…
The pharmaceutical industry stands at the threshold of a long-overdue transformation in how serialization is approached, implemented, and managed. For more than a decade, serialization has largely been driven by compliance, delivering solutions that meet regulatory requirements but offer limited value beyond the legal minimum. Today, however, the world of…
Temperature-Sensitive Tech: Cold Chain's Continuous Development
PC: You recently delivered a keynote presentation surrounding “How to Integrate E2E and Deliver ‘Miracles of Science’ to your Patients.” Could you provide a brief synopsis of what your session entailed? Beadle: Sanofi is undergoing a major transformation with the ambition to become the first biopharma company powered by AI…
Key Takeaways Personalized medicine demands precision logistics, with strict temperature control, real-time tracking, and regulatory compliance essential to ensure safe and timely delivery of patient-specific therapies. Gaps in last-mile delivery and third-party training pose serious risks, especially when handling temperature-sensitive, irreplaceable treatments for critically ill patients. Advanced technologies like predictive…
HPV Vaccine: Balancing Benefits, Risks, and Public Perception Despite ongoing lawsuits and public concerns about serious adverse events, current evidence supports the safety and effectiveness of the human papillomavirus vaccine in preventing a wide range of cancers, underscoring the need for continued public health advocacy and open patient-provider communication. Pfizer-backed…
In a video interview with Pharma Commerce, Kevin Dondarski, Deloitte’s life sciences R&D strategy leader, describes how his company’s 15th annual Deloitte report on the return on investment (ROI) in pharmaceutical R&D reveals a continued upward trend, with a projected ROI of 5.9% for 2024. This marks a notable reversal…
Image Credit: Adobe Stock Images/PeterHansen.com Key Takeaways Noom is now offering its own compounded version of semaglutide—an active ingredient in Wegovy and Ozempic—through its telehealth marketplace. The FDA has ended the semaglutide shortage and set a May 22 deadline for compounders to cease production. Noom argues for a “personalized” exception,…
PC: How would you define successful E2E, and what specific processes are necessary in order to achieve this? Beadle: The first thing I’d highlight—and I mentioned this in the keynote—is that we are a company of scale and history. It’s hard to visualize that scale without digitization. We’ve moved away…
Bridging Innovation and Trust with Artificial Intelligence In a recent interview with Applied Clinical Trials, Michel van Harten, MD, CEO of myTomorrows, discussed how AI is transforming clinical trials by reducing costs, accelerating timelines, and enhancing patient inclusion—while emphasizing the need for data quality, transparency, and trust to ensure responsible…
Credit: Production Perig | stock.adobe.com Key Takeaways Embrace Real-Time Data for Proactive Supply Chain Management. Advanced manufacturing and real-time analytics help pharmaceutical companies predict and prevent drug shortages. Just like in retail, real-time demand tracking and inventory optimization ensure essential medications are available when needed. Leverage Automation and AI for…
The Role of AI in Solving Clinical Trial Diversity and Access Challenges In an interview with Applied Clinical Trials, Michel van Harten, MD, CEO of myTomorrows, explained how AI can help address clinical trial diversity and access challenges by reducing physician workload through treatment matching, simplifying patient education, and breaking…
PC: How do you see the potential impact of HHS’s proposed policy change on patient advocacy efforts, particularly for rare and serious diseases? Leuchter: If I step back and think about how critical it is to receive input, feedback, and partnership from patient advocates—their voice is truly essential—it’s hard to…
Main Takeaways 503B outsourcing facilities must comply with various FDA regulations, including current good manufacturing practices (cGMP), registration, labeling, and adverse-event reporting requirements, which distinguish them from 503A pharmacies and enable them to mass-produce and distribute compounded drugs for office use without patient-specific prescriptions. The FDA’s increased oversight has raised…
In a video interview with Pharma Commerce, Kevin Dondarski, Deloitte’s life sciences R&D strategy leader, describes how his company’s 15th annual Deloitte report on the return on investment (ROI) in pharmaceutical R&D reveals a continued upward trend, with a projected ROI of 5.9% for 2024. This marks a notable reversal…
Image Credit: © JHVEPhoto – stock.adobe.com Key takeaways Placebo-controlled trials now required for low-risk groups: FDA will require placebo-controlled trials for COVID-19 vaccines in low-risk populations before granting full approval—adding complexity to trial design, ethics reviews, and recruitment. New focus on clinical outcomes & longer follow-up: Trials must now measure…
Less is More in Clinical Data: The Road to Simpler and Better Trials In an article for Applied Clinical Trials, Drew Garty, chief technology officer, Veeva, emphasizes that simplifying clinical trial data management through pragmatic strategies—like endpoint-driven design, risk-based approaches, and smart automation—can reduce waste, improve site and patient experiences,…
Image Credit: Adobe Stock Images/Weerasak.com The Low-Income Subsidy, or “Extra Help,” significantly reduces prescription drug costs for 14 million Medicare beneficiaries with limited income and resources. The Inflation Reduction Act eliminated the partial LIS program, making full benefits available to individuals with incomes up to 150% of the federal poverty…
In a video interview with Pharma Commerce, Kevin Dondarski, Deloitte’s life sciences R&D strategy leader, describes how his company’s 15th annual Deloitte report on the return on investment (ROI) in pharmaceutical R&D reveals a continued upward trend, with a projected ROI of 5.9% for 2024. This marks a notable reversal…
Image Credit: Adobe Stock Images/GorodenKoff.com Invensify and GO2 Delivery’s partnership significantly reduces cold chain packaging costs—by up to 50%—while ensuring regulatory compliance for temperature-sensitive medications. The collaboration promotes sustainable healthcare logistics through real-time tracking and fully carbon-neutral same-day delivery operations. Invensify, a cold chain shipper for healthcare supply chains, is…
Navigating the Payer-Health System Nexus: A Strategic Imperative for Biopharma Commercial Success Biopharma companies must adopt integrated strategies that engage both payers and health systems—each now powerful, parallel decision-makers—to overcome hidden barriers like “shadow formularies” and ensure successful therapeutic adoption in today’s vertically integrated healthcare landscape, according to a feature…
White House Unveils Pharma Most-Favored-Nation Executive Order Pharmaceutical Executive reported that President Trump issued an executive order titled Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients, aiming to lower US drug prices by requiring pharmaceutical companies to match or beat prices offered in other developed countries, with potential penalties including…
Image Credit: Adobe Stock Images/LucianoLuppa.com 1. Leadership shakeup amid crises: UnitedHealth Group CEO Andrew Witty has abruptly stepped down, citing personal reasons. His departure follows a year of major turmoil for the company, including a DOJ investigation, a massive cyberattack affecting 190 million people, and the murder of a senior…
Image Credit: Adobe Stock Images/Suriyo.com 1. Five-step repurposing process: The study outlined a five-stage process: enabling, identifying, validating, testing, and implementing repurposed drugs. 2. RDNPs drive success: Nonprofit involvement, especially in patient recruitment, was linked to successful repurposing outcomes, including FDA approvals and off-label use. 3. New DDDR Framework: Researchers…
A Closer Look at NIH Grant Terminations In an interview with Applied Clinical Trials, Harvard Medical School researcher Michael Liu discussed a recent study analyzing NIH grant terminations, revealing that 20% of the cuts affected early career training grants—critical to the biomedical research pipeline—and disproportionately impacted institutions and clinical trials…
Pharmaceutical Commerce: What specific pricing practice by pharmacy benefit managers (PBMs) does the Protecting Pharmacies in Medicaid Act aim to address? Anne Cassity: The Protecting Pharmacies in Medicaid Act really aims at getting rid of spread pricing and the Medicaid managed care programs in every state in the country. Spread…
In a video interview with Pharma Commerce, Kevin Dondarski, Deloitte’s life sciences R&D strategy leader, describes how his company’s 15th annual Deloitte report on the return on investment (ROI) in pharmaceutical R&D reveals a continued upward trend, with a projected ROI of 5.9% for 2024. This marks a notable reversal…
PC: As the head of global supply chain, what does your day-to-day workflow typically consist of? Beadle: Our primary responsibility is getting products to patients—that’s at the heart of what we do. Every day, I focus on identifying potential challenges and working with my team to mitigate risks, ensuring patients…
Five questions on Trump’s plan to lower US drug prices President Trump’s new plan to lower US drug prices by tying them to the lowest prices paid in other countries aims to fulfill campaign promises and pressure the pharmaceutical industry, but faces significant legal, political, and economic hurdles, with uncertain…
In a video interview with Pharma Commerce, Kevin Dondarski, Deloitte’s life sciences R&D strategy leader, describes how his company’s 15th annual Deloitte report on the return on investment (ROI) in pharmaceutical R&D reveals a continued upward trend, with a projected ROI of 5.9% for 2024. This marks a notable reversal…
Bluebird bio warns of potential bankruptcy as buyout faces another delay Bluebird bio has warned of possible bankruptcy after buyers Carlyle and SK Capital extended their acquisition deadline yet again due to insufficient shareholder participation, as only about 26% of shares have been tendered—far below the required threshold to complete…
Image Credit: Adobe Stock Images/MAlfanSetyawan.com It’s no secret that for years, critics have commented about the prices for medication in the UnitedStates being exorbitantly high. In response to this issue, President Donald Trump yesterday unveiled a new executive order (EO)—Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients”1—meant to provide an…
In a video interview with Pharma Commerce, Michael Rowe, Two Labs’ senior director of DSCSA/serialization compliance services, describes how the HDA Distribution Management Conference (DMC) covers a broad spectrum of topics within the pharmaceutical supply chain, with a special focus on current regulatory and operational challenges. One of the major…
Rendering of the new Lexington sterile fill-finish facility. Image Credit: Piramal Pharma Ltd. Piramal Pharma Limited, a global pharmaceuticals and wellness company, will be investing $90 million toward growing two of the company’s plants located in the United States: Lexington, KY, and Riverview, MI.1 The expansion projects are coming into…
FDA chief Martin Makary sets June deadline for genAI rollout FDA Commissioner Martin Makary has set a June 30, 2025 deadline for full agency-wide rollout of generative AI to streamline scientific reviews and reduce bureaucratic workload, amid concerns about whether the technology can offset recent staffing cuts under HHS Secretary…
In a video interview with Pharma Commerce, Michael Rowe, Two Labs’ senior director of DSCSA/serialization compliance services, describes how the HDA Distribution Management Conference (DMC) covers a broad spectrum of topics within the pharmaceutical supply chain, with a special focus on current regulatory and operational challenges. One of the major…
Teva plots thousands of job cuts as restructuring drive enters ‘acceleration’ phase Teva is set to cut around 2,400 jobs, about 8% of its workforce, as part of its “Acceleration Phase” in the ongoing restructuring plan aimed at saving $700 million by 2027, streamlining operations, and strengthening its position in…
In this video, Josh Marsh, Vice President and General Manager of Cardinal Health Sonexus™ Access and Patient Support, discusses the balance between technology and human interaction to support patients and programs. Patient support program strategies must be tailored to the unique needs of each patient journey, while aligning with the…
In a video interview with Pharma Commerce, Michael Rowe, Two Labs’ senior director of DSCSA/serialization compliance services, describes how the HDA Distribution Management Conference (DMC) covers a broad spectrum of topics within the pharmaceutical supply chain, with a special focus on current regulatory and operational challenges. One of the major…
The latest wave of artificial intelligence (AI), digital health, and direct-to-patient (DTP) models have the potential to drive significant innovation, transform patient experiences, and redefine business and operating models across life science companies. Estimates show that AI alone could drive value equivalent to 11% of current revenue for a typical…
J&J survey finds pace of oncology innovation is overwhelming physicians A recent J&J survey reveals that oncologists are overwhelmed by the rapid pace of oncology innovation, highlighting the need for additional support and continuing medical education to help them keep up with new treatments and guidelines. Biotech is guessing how…
The ETF-300. Image Credit: Antares Vision Group Antares Vision Group, a provider of track-and-trace systems for several fields including the life sciences, is growing its solutions portfolio to now include precision labeling equipment. The company is collaborating with Siempharma, a manufacturer of packaging machines, by welcoming the ETF-300.1 This machine…
In an interview with Pharmaceutical Commerce, a session leader from “U.S. Pharmaceutical Transitions: What’s Next?” shared key insights on the current and future state of the market. The conversation highlighted the rapid growth of specialty pharmaceuticals—now comprising over half of the total market—and examined critical industry developments ranging from biosimilar uptake…
Image Credit: Adobe Stock Images/N0m3rcy.com SK pharmteco, a contract development and manufacturing organization (CDMO), has opened a new, 300,000 square-foot current good manufacturing practice (CGMP) plasmid suite at its plant in King of Prussia, PA.1 The project demonstrates the company’s interest in a scalable supply of high-quality plasmids, which are…
In an interview with Pharmaceutical Commerce, Fran Gregory, VP, emerging therapies, Cardinal Health, shared key insights into the evolving landscape of cell and gene therapies. Speaking about the current state of the market, the anticipated growth of the pipeline, and the critical steps needed to ensure long-term sustainability, Gregory highlighted both…
At this year’s Asembia Summit, Pharmaceutical Commerce sat down with Blake Powers, CEO of Medigi, to discuss the company’s role in bridging innovation and patient access in the life sciences space. Powers shared his insights on the evolving landscape of commercialization, the growing importance of digital health and automation, and how in-person…
As the healthcare industry sharpens its focus on patient-centered care, addressing social determinants of health, health equity, and literacy has become more critical than ever—particularly for individuals with chronic and rare conditions. During the “Speaking Health and Human: Bridging the Gap to Quality Patient Care” session, Tiara Green will join industry leaders…
In an interview with Pharmaceutical Commerce, Chip Parkinson, the new CEO of Gift Health, shared his perspective on stepping into the role and the evolving challenges and opportunities across the healthcare landscape. Drawing on a diverse background that spans manufacturers, payers, and employer consulting, Parkinson discussed how his new position places…
Being proactive with and responsive to your environmental monitoring (EM) data helps prevent problems with cleanroom contamination. Learn more about EM and cleanroom best practices and to see how ABM can implement industry-leading cleanroom solutions for your facility.
March 14th 2025 Article A regional hospital serving suburban Indianapolis, Hancock Regional Hospital faced a familiar challenge: disparate monitoring systems that taxed their staff and too many manual processes that drove inefficiencies. CEO Steve Long greenlit a solution: a consolidated temperature, environmental, and sound monitoring program that protected precious assets,…
Image Credit: Nicholas Saraceno The afternoon of day 2 at Asembia’s AXS25 Summit offered various intriguing sessions to pick from, including one on “Navigating the IRA: What Have We Learned? What is on the Horizon?” The IRA—or Inflation Reduction Act—is a federal law passed in 2022 that, among its various…
April 30, 2025 Amy Niles, chief mission officer, PAN Foundation, discusses the latest changes to the Medicare program that have the potential to improve patient access to care, along with the work needed to generate awareness about them.
Image Credit: Nicholas Saraceno The final day of education at Asembia’s AXS25 Summit kicked off with a multitude of early morning sessions, including one focused on “Beyond Limits: Rethinking Drug Distribution to Drive Patient-Centered Care.” Led by Mike Reff, RPh, MBA, executive director and founder of NCODA (Network for Collaborative…
Multimorbidity and associated polypharmacy, including use of potentially inappropriate medication (PIM), are an increasing challenge for European health systems. A lack of cross-national studies using standardized methodology and comparable study populations makes it difficult to determine the prevalence of polypharmacy and PIM use in primary care across Europe. In a…
Image Credit: Nicholas Saraceno The afternoon sessions here on day 3 of Asembia continued its impressive slate, with its various business seminars as proof. One of which was centered around “The Cost of Care for Patients: Navigating the Financial Assistance Landscape.” Moderated by Amy Niles, chief mission officer of the…
The second day of Asembia’s AXS25 Summit featured a session that addressed a distinct set of challenges facing the pharmaceutical industry. Titled “Beyond the Headlines: What Pharma Leaders Must Know About Tariffs, Supply Chains, and Policy Changes,” the discussion highlighted how evolving global instability, policy shifts, and supply chain vulnerabilities…
In an interview with Pharmaceutical Commerce, Fran Gregory, VP, emerging therapies, Cardinal Health, shared key insights into the evolving landscape of cell and gene therapies. Speaking about the current state of the market, the anticipated growth of the pipeline, and the critical steps needed to ensure long-term sustainability, Gregory highlighted…
In an interview with Pharmaceutical Commerce, Will Pih, co-founder, Two Labs, shared insights from his recent panel discussion on “Economics and Specialty Pharmacy for Rare Diseases: Challenges and Opportunities.” The conversation explored the growing complexities of delivering care in the rare disease space, particularly as specialty pharmacies and pharmaceutical manufacturers…
In an interview with Pharmaceutical Commerce, a session leader from “U.S. Pharmaceutical Transitions: What’s Next?” shared key insights on the current and future state of the market. The conversation highlighted the rapid growth of specialty pharmaceuticals—now comprising over half of the total market—and examined critical industry developments ranging from biosimilar…
Image Credit: Nicholas Saraceno Here at Asembia’s AXS25 Summit in Las Vegas, attendees were treated to behind-the-scenes insight regarding “Commercialization Considerations for Orphan/Rare, Cell & Gene, and Precision Medicine.” Led by Brett Casper, a senior principal at Blue Fin Group, his agenda revolved around outlining the evolving orthodoxies for commercialization…
As the healthcare industry sharpens its focus on patient-centered care, addressing social determinants of health, health equity, and literacy has become more critical than ever—particularly for individuals with chronic and rare conditions. During the “Speaking Health and Human: Bridging the Gap to Quality Patient Care” session, Tiara Green will join…
In a video interview with Pharma Commerce, Paul Levesque, CEO of Theratechnologies, explains how Theratechnologies’ operations have been impacted by recent US tariffs on Canadian goods, especially concerning the manufacturing and supply chain for its HIV therapy, EGRIFTA SV. The active ingredients used in EGRIFTA SV come from the US,…
Regeneron, Roche Launch Major US Expansion Plans to Meet Growing Demand for Biologics and Innovation Regeneron and Roche are investing a combined $53 billion over the next decade to expand US manufacturing and R&D infrastructure—spanning biologics, gene therapy, AI-driven research, and next-gen therapeutics—in response to rising global demand and potential…
In a video interview with Pharma Commerce, Paul Levesque, CEO of Theratechnologies, explains how Theratechnologies’ operations have been impacted by recent US tariffs on Canadian goods, especially concerning the manufacturing and supply chain for its HIV therapy, EGRIFTA SV. The active ingredients used in EGRIFTA SV come from the US,…
Understanding the True Meaning of Risk in Clinical Trial Operations In a recent interview with Applied Clinical Trials, Rob Jones of Pharmalex emphasized the need for TMF leaders to adopt a truly risk-based, quality-by-design mindset. This includes embracing innovations such as AI, focusing on critical records, and adapting to rapidly…
Roche in ‘Very, Very Good Position’ To Weather Trump Tariffs but M&A May Suffer Roche expects to weather the financial impact of Trump-era tariffs due to its strategic US manufacturing shifts and global investments, though M&A activity may slow as the industry assesses the tariffs’ broader implications. Thermo Fisher To…
In a video interview with Pharma Commerce, Paul Levesque, CEO of Theratechnologies, explains how Theratechnologies’ operations have been impacted by recent US tariffs on Canadian goods, especially concerning the manufacturing and supply chain for its HIV therapy, EGRIFTA SV. The active ingredients used in EGRIFTA SV come from the US,…
Claire Riches highlights inefficiencies in the current drug approval process, while outlining the role of payers and insurers in shifting toward data-driven approval framework.
In a video interview with Pharma Commerce, Paul Levesque, CEO of Theratechnologies, explains how Theratechnologies’ operations have been impacted by recent US tariffs on Canadian goods, especially concerning the manufacturing and supply chain for its HIV therapy, EGRIFTA SV. The active ingredients used in EGRIFTA SV come from the US,…
Image Credit: Business Wire PCI Pharma Services, a contract development and manufacturing organization (CDMO), will be purchasing a full stake in Ajinomoto Althea, Inc., a sterile fill-finish CDMO and subsidiary of Japan-based Ajinomoto Co., Inc., for an undisclosed amount.1 The deal is anticipated to be completed by May, and gives…
Image Credit: Adobe Stock Images/OMS.com The International Air Transport Association (IATA) is celebrating 10 years of its Center of Excellence for Independent Validators (CEIV) program, which evaluates a company’s the air cargo supply chain efforts when it comes to quality, safety, and compliance.1 CEIV was officially launched in 2014 alongside CEIV…
PC: How can stakeholders ensure that sustainability takes precedence, even over other important business drivers? Ganguly: There are three key takeaways from the panel—and from observing how the sustainability movement has evolved. First, it’s important to share practical proof points. In the early stages, we saw a lot of pledges,…
Image Credit: Adobe Stock Images/Kotchakorn.com Among the older population, polypharmacy—the use of five or more medications—has skyrocketed. The issue lies in the fact that some meds lack any sort of indication, are used in way too high of a dose, or do more harm than good. These are considered “inappropriate.”…
PC: You just wrapped up a panel discussion on “Uniting on Sustainability: How can we drive collaboration and ground-breaking initiatives to ensure ESG is a top business priority?” With sustainability being such a priority nowadays, what were some the highlights of the presentation? Ganguly: The panel was actually really refreshing…
In a video interview with Pharma Commerce, Jody Hatcher, CEO of Morris & Dickson and chair of HDA’s board of directors, outlines his vision for the future of the organization and the key priorities he hopes to drive during his tenure. He expresses a strong sense of privilege and responsibility…
Image Credit: Thermo Fisher Scientific Thermo Fisher Scientific has officially opened its Advanced Therapies Collaboration Center (ATxCC) in Carlsbad, CA.1 The plant is intended to speed up both the development and commercialization of cell therapies, in an effort to both grow the life sciences space and improve patient outcomes. As…
In a video interview with Pharma Commerce, Rachel Thorpe, executive director at the Otsuka Patient Assistance Foundation, discusses two key sessions: “Establishing and Transitioning to a Foundation” and “Empowering Patients to Take Control of Their Healthcare.” The first session focuses on the important aspects of transitioning to a foundation, emphasizing…
Pharma companies expected to absorb any tariff hit in short term While US tariffs on pharmaceuticals may eventually raise drug prices, especially for generics, experts say brand-name costs will likely be absorbed by manufacturers in the short term—impacting profits, research, and staffing—while the broader goal may be to pressure companies…
Image Credit: Adobe Stock Images/Monchisa The FDA has granted interchangeability designation to Celltrion’s Yuflyma (adalimumab-aaty), a high-concentration (100 mg/mL), citrate-free biosimilar of Humira (adalimumab), across multiple inflammatory indications. The designation allows pharmacists, subject to state laws, to substitute Yuflyma for Humira without prescriber intervention, which could potentially improve access and…
Bringing Biotech Innovation Across Borders A feature published by Pharmaceutical Executive authored by Ed Ahn, CEO of MEDIPOST, Inc, outlines four tips for midsized companies when entering new global markets. The Role of Collaboration in Advancing Rare Disease Research In this video interview published by Applied Clinical Trials, Derek Ansel,…
In a video interview with Pharma Commerce, Jody Hatcher, CEO of Morris & Dickson and chair of HDA’s board of directors, outlines his vision for the future of the organization and the key priorities he hopes to drive during his tenure. He expresses a strong sense of privilege and responsibility…
For a child with autism spectrum disorder (ASD), effective care coordination across the required medical, physical rehabilitation, counseling, occupational, and speech providers is challenging, especially when the aim is to provide individualized care—at scale across many patients. Genial Care, a healthcare company focusing on personalized interventions for children with ASD,…
In a video interview with Pharma Commerce, Jody Hatcher, CEO of Morris & Dickson and chair of HDA’s board of directors, outlines his vision for the future of the organization and the key priorities he hopes to drive during his tenure. He expresses a strong sense of privilege and responsibility…
PC: How do you manage to keep the program itinerary organized year after year? Robinson: While we have a broader global LogiPharma portfolio, my team now focuses solely on this event. These days, it’s a year-round project—365 days. Once this year’s event wraps, I’ll be thanking our speakers and delegates…
Image Credit: Adobe Stock Images/Metamorworks.com There is a new contract development and manufacturing organization (CDMO) in the marketplace. With the ultimate goal of boosting patient health through its manufacturing services, Meribel Pharma Solutions has officially launched, bringing with it a European network of clients.1 The name comes from the Meribel mountain range…
PC: When comparing this year to previous years, how would you say the main discussion points of LogiPharma have evolved? Robinson: I’m sure I’m not the only one saying this, but the big one is AI. The pace of growth in machine learning and automation has been incredible—even just compared…
Pharmaceutical Commerce: April 2025 Interactive Digital Edition The Cold Chain’s Evolution Tariffs Galore: Where Do We Stand? Conference Connect: Progressing Patient Assistance The Hot Market for Cold Chain Services Reducing Risk in the Pharmaceutical Cold Chain An AI-Pharma Transport Collaboration The Role of CDMOs in the Pharma Cold Chain Machine…
PC: What was the thought process behind moving LogiPharma to Vienna in 2026? Robinson: First and foremost, it’s about the capabilities of the venue. Lyon has been wonderful and has served us well, but we’re looking to expand the agenda to include more intimate, focused discussions. With around 2,200 attendees,…
The pharmaceutical cold chain sector plays a crucial role in ensuring the safe and effective delivery of temperature-sensitive medications, including advanced therapy medicinal products (ATMPs). For the last decade, it’s been crucial for contract development and manufacturing organizations (CDMOs) to adopt the latest technological advances to enhance the efficiency and…
Logistics play a very important role in the pharmaceutical industry, as the activities involved are highly sensitive to time and quality control. It involves delivering drugs to the right place, at the right time, in a safe and secure manner, and at a competitive operational cost. Given this crucial nature…
PC: What general advice do you have for other pharma supply chain stakeholders when it comes to delivering change that boosts growth, augments pipelines, and increases productivity? Lang: First of all, I think there needs to be alignment and a clear understanding at the executive level that operations is a…
Long-Term Sustainability for Diverse Trial Initiatives LaShell Robinson, head of global feasibility and trial equity at Takeda, discusses how Takeda will ensure that diversity and inclusion remain a priority in its clinical trials moving forward. Payers Consider Policy Options for Access to GLP-1 Obesity Medications A new paper by the…
In a video interview with Pharma Commerce, Kimberly Westrich, MD, chief strategy offer at the National Pharmaceutical Council, describes how in response to rising healthcare costs, employers have turned to high-deductible health plans and higher out-of-pocket (OOP) expenses, causing patients to pay more for healthcare. To help alleviate this financial…
PC: How can technology play a role in implementing these changes, and what challenges can it help overcome? Lang: Technology has fundamentally changed our lives outside of work—and it has also brought significant transformation and opportunity within the workplace. In operations, we always assess technology through the lens of how…
One of the objections I sometimes hear when discussing counterfeiting and diversion challenges with pharmaceutical manufacturers, particularly smaller ones, is that they just don’t know enough about the problem. They may suspect they have a problem and/or they may have seen some evidence of a problem, but they feel they…
Let’s start with an alarming pair of statistics. First, 40% of specialty product prescriptions actually get filled, and second, when a patient’s copay or out-of-pocket cost exceeds $250, the abandonment rate is nearly 70%. Pharmaceutical manufacturers are focused on making massive investments in product launches, field force training, marketing, and…
Welcome to the third installment of my “Popping the Gross-to-Net Bubble” series. In my previous column, I explored actionable steps pharmaceutical manufacturers can take to address gross-to-net (GTN) challenges for products reimbursed under the medical benefit. This time, I focus on products reimbursed under the pharmacy benefit. The complexity of…
Healthcare costs, insurance barriers, and medical debt are preventing patients with chronic illnesses in the US from accessing essential treatments and medications. That’s according to the PAN Foundation’s Center for Patient Research State of Patient Access Report initiative. The latest survey1, released in March, found patients living with chronic health…
Image Credit: Nicholas Saraceno LogiPharma Europe continued its star-studded lineup featuring Big Pharma, with a morning keynote case study on “Rethinking Your C> Value Chain: How to Ensure Readiness for Evolving Specialized Therapy Requirements.” Led by Graham White, BMS’ executive director of global delivery for Europe, the Middle East, and…
When I was penning my latest column for Pharma Commerce, I felt that various recent developments were worth noting, considering the impact they could have on the US prescription drug market. They include the drug industry’s push to make Inflation Reduction Act (IRA) changes to the “pill penalty” and negotiation…
The COVID-19 pandemic highlighted our supply chains’ weaknesses like never before. A sudden surge in demand and limited production capabilities led to critical shortages of medical supplies, pharmaceuticals, and even basic consumer goods. For life sciences, this disruption wasn’t just a matter of lost revenue—it was a matter of life…
Developing effective lifesaving drugs requires significant research and development (R&D) investments. New medications cost an average of $2.3 billion to develop,1 largely funded by existing drug sales. At the same time, pharmaceutical companies are under increasing pressure from the government to reduce prescription prices, which presents a significant hurdle to…
In a video interview with Pharma Commerce, Kimberly Westrich, MD, chief strategy offer at the National Pharmaceutical Council, describes how in response to rising healthcare costs, employers have turned to high-deductible health plans and higher out-of-pocket (OOP) expenses, causing patients to pay more for healthcare. To help alleviate this financial…
Image Credit: Adobe Stock Images/MichaelVi Boehringer Ingelheim announced the official opening of a new antibody-drug conjugate (ADC) research and development facility in Basel, Switzerland, through its wholly owned subsidiary, NBE Therapeutics. According to the company, the $31.5 million facility will serve as a global hub for advancing the development of…
Balancing Cost-Efficiency with the Need for Domestic Manufacturing Marcel Botha, CEO of 10XBeta, discusses finding a balance between the need for cost-efficiency and the need to build domestic manufacturing capacity for essential medical devices. Making M3P Work for Your Pharmacy: A Guide to Streamlining Enrollment and Supporting Patients M3P will…
Analyzing the Theranos Appeals Matthew Yelovich, partner at Cleary Gottlieb, discusses the appeals of Elizabeth Holmes and Ramesh “Sunny” Balwani and the Ninth Circuit’s recent affirmation of their convictions. Current CAR-T Therapy Trends in Managed Care | AMCP Annual 2025 Balancing the cost, access to and risk management of CAR-T…
In a video interview with Pharma Commerce, Rachel Thorpe, executive director at the Otsuka Patient Assistance Foundation, discusses two key sessions: “Establishing and Transitioning to a Foundation” and “Empowering Patients to Take Control of Their Healthcare.” The first session focuses on the important aspects of transitioning to a foundation, emphasizing…
Google Gemini, AI Commercialization in Pharma and More Google recently released an updated version of its AI LLM. Gemini 2.5 Pro boasts a variety of new features that could help integrate AI even more into various workflows. It is still a tool, however, and in order to get the best…
In a video interview with Pharma Commerce, Colin Banas, MD, DrFirst’s chief medical officer, describes have many Americans face significant challenges in accessing GLP-1 drugs due to their high cost. Despite the growing popularity and usage of these medications, which were originally developed for diabetes treatment, the price remains largely…
Image Credit: Adobe Stock Images/Tun.com Siemens AG, a technology conglomerate, has acquired Dotmatics, an R&D scientific software company, from private equity firm Insight Partners for $5.1 billion.1 “By acquiring Dotmatics, we’re strategically strengthening our position in life sciences and creating a world-leading AI-powered PLM software portfolio as part of Siemens…
In a video interview with Pharma Commerce, Colin Banas, MD, DrFirst’s chief medical officer, describes have many Americans face significant challenges in accessing GLP-1 drugs due to their high cost. Despite the growing popularity and usage of these medications, which were originally developed for diabetes treatment, the price remains largely…
Image Credit: Adobe Stock Images/Bashirlrshad.com Yesterday afternoon, as reported by AP,1 US President Donald Trump announced that he will be enacting reciprocal tariffs on countries that are running trade surpluses with the United States—which is when the value of its exports exceeds the value of its imports. In other words,…
In a video interview with Pharma Commerce, Kimberly Westrich, MD, chief strategy offer at the National Pharmaceutical Council, describes how in response to rising healthcare costs, employers have turned to high-deductible health plans and higher out-of-pocket (OOP) expenses, causing patients to pay more for healthcare. To help alleviate this financial…
Image Credit: Adobe Stock Images/Douglas.com A Reuters report1 noted that Hims & Hers began selling various Eli Lilly drugs on their platform—both branded forms of tirzepatide—including Zepbound, a glucagon-like peptide-1 (GLP-1) receptor agonist approved by the FDA for weight loss, and Mounjaro, which is not approved for weight loss but…
In the first part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Colin Banas, MD, DrFirst’s chief medical officer, discusses the challenges that many Americans face regarding the affordability of GLP-1 drugs.
Oscar de Bok, CEO of DHL Supply Chain, and Jerrell Shelton, CEO of Cryoport. Image Credit: DHL Supply Chain DHL has purchased CRYOPDP, Cryoport’s specialty courier powered by clinical trials, biopharma, and cell and gene therapies.1 In that same breath, the parties also noted that they’ve reached a strategic partnership…
PC: What are some of the biggest challenges in ensuring continued medication adherence for specialty patients? Butler: While technology and high-touch support are important, personalization is equally critical. Emotions fluctuate daily, and medication regimens, as well as chronic conditions, evolve over time. Whenever we implement a solution, we must continuously…
Renier Brentjens, MD, PhD outlines the evolution of the space, while offering ways to boost patient access to these treatments.
PC: How is the role of patient engagement evolving in specialty pharmacy? Butler: It’s becoming increasingly critical to evolve patient support in specialty pharmacy, as patients now expect more personalized care. With the rapid advancement of technology, they also anticipate greater connectivity. While access to information is beneficial, it can…
Image Credit: Singota Solutions Following the launch of last year’s site in Rovello Porro, Italy,1 Singota Solutions, a contract development and manufacturing organization (CDMO), has opened a new 100,000 square-foot plant in Balerna, Switzerland.2 Balerna is located near the Swiss-Italian border, providing the CDMO’s customers with a convenient location for…
PC: What are some common barriers patients face when starting specialty medications, and how can peer-to-patient outreach help? Butler: Our program is a peer-to-patient platform, which I believe is critical. It addresses emotional barriers such as fear, misinformation, mistrust, anxiety, feeling overwhelmed, not knowing who to turn to, uncertainty about…
Image Credit: Adobe Stock Images/Orawan.com Eli Lilly and Company is growing its LillyDirect digital healthcare platform to offer independent in-person and telehealth support for people in the United States that are living with Alzheimer’s disease, many of whom may have not been officially diagnosed.1,2 Clinicians and those living with Alzheimer’s disease have…
PC: How does Pleio’s GoodStart program assist specialty pharmacies in improving patient engagement and adherence? Butler: Onboarding onto specialty medications is a complex and often overwhelming process for patients. That’s the core challenge Pleio addresses with our GoodStart program. We focus on delivering patient-centric support to specialty pharmacies through a…
Image Credit: Adobe Stock Images/Pier.com Combined with research and manufacturing agreements, AstraZeneca is investing $2.5 billion into its sixth global strategic research & development (R&D) center in Beijing.1 The five-year financial commitment is part of a deal with the Beijing Municipal Government and the Beijing Economic-Technological Development Area Administrative Office.…
In a video interview with Pharma Commerce, Brad Stewart, BDO’s national life sciences co-leader, describes the challenges that tariffs may pose to reshoring manufacturing services in the life sciences industry. He highlights the complexity of supply chains in this sector, which are large, long, highly-regulated, and slow to change. Given…
Image Credit: Adobe Stock Images/Gaming.com Although the United States spends an exorbitant amount on healthcare, amounts across the individual states vary. In fact, studies have so that there are some counties that spend more than five times as much per person as other counties.1,2 Such variety in public, commercial, and…
Charitable donations have long been a vital lifeline for patients struggling to afford life-saving medications, particularly those with chronic and rare diseases. Over the past few decades, various assistance programs—including nonprofit safety nets, third-party organizations, and manufacturer-sponsored free drug initiatives—have emerged to bridge the gap between medical advancements and patient…
Image Credit: Nicholas Saraceno The final day of Informa’s Access USA conference arrived quickly, and I decided to attend a session along the Hubs East track focused on “The Changing Landscape of Patient Access—Accumulators, Maximizers & Alternative Funding.”1 Featuring Meredith McDonald, director of patient access, Exelixis; Kimberly Westrich, National Pharmaceutical…
Image Credit: Nicholas Saraceno Informa’s Access USA conference from Philadelphia continued with its first panel discussion of the conference. Amy Niles, chief mission officer of the PAN Foundation—a national charitable foundation and healthcare advocacy group—was joined by Bill Allen, a patient and family advisory council member with PAN Foundation; Susan…
Charitable donations have long been a vital lifeline for patients struggling to afford life-saving medications, particularly those with chronic and rare diseases. Over the past few decades, various assistance programs—including nonprofit safety nets, third-party organizations, and manufacturer-sponsored free drug initiatives—have emerged to bridge the gap between medical advancements and patient…
New Ways of Targeting Cancer Company executives provide updates on cancer treatment pelareorep and other elements of the company’s pipeline. How Employers Can Support Employee Well-Being and Mental Health Trust remains a sensitive subject amongst employees as the shortage of mental health resources makes it even harder for them to…
The 2025 Medication Access Report: Biggest Bottlenecks for Patients Kimberley Chiang, vice president of biopharma commercial solutions at CoverMyMeds, highlights gaps in data sharing and cross-functional collaboration as major bottlenecks that are causing delays, rework, and increased patient burden. Age and Comorbidities Drive RSV Hospitalization Rates in Older Adults Prioritizing…
Charitable donations have long been a vital lifeline for patients struggling to afford life-saving medications, particularly those with chronic and rare diseases. Over the past few decades, various assistance programs—including nonprofit safety nets, third-party organizations, and manufacturer-sponsored free drug initiatives—have emerged to bridge the gap between medical advancements and patient…
Image Credit: Nicholas Saraeno Day 2 of Informa’s Access USA track-based coverage carried on, with an afternoon session on the PAP track being run by Rachel Thorpe, executive director at the Otsuka Patient Assistance Foundation, an independent entity from the manufacturer Otsuka. Focusing on “Empowering Patients to Take Control of…
Image Credit: Nicholas Saraceno Day 2 of Informa’s Access USA conference represented the start of its track-based sessions. In terms of the patient assistance & access program (PAP) focus of the conference, Aaron Winn, associate professor at the University of Illinois Chicago, led off the morning with a presentation centered…
Charitable donations have long been a vital lifeline for patients struggling to afford life-saving medications, particularly those with chronic and rare diseases. Over the past few decades, various assistance programs—including nonprofit safety nets, third-party organizations, and manufacturer-sponsored free drug initiatives—have emerged to bridge the gap between medical advancements and patient…
Charitable donations have long been a vital lifeline for patients struggling to afford life-saving medications, particularly those with chronic and rare diseases. Over the past few decades, various assistance programs—including nonprofit safety nets, third-party organizations, and manufacturer-sponsored free drug initiatives—have emerged to bridge the gap between medical advancements and patient…
Image Credit: Nicholas Saraceno Informa’s Access USA Conference leveraged its KOL base with a roundtable on “Unravelling the Complexities of Patient Access and Affordability.”1 Featuring Ian Ocilka, ConnectiveRx’s chief strategy officer as moderator, he was accompanied by Nancy Bell, vice president and head of US patient value & access at Takeda…
Image Credit: Nicholas Saraceno Day 1 of Informa’s Access USA Conference from Philadelphia—featuring Patient Assistance & Access Programs (PAP) and Hub and Specialty Models East—was kicked off by Tommy Bramley, Cencora’s SVP of global consulting services. Titled “State of the Industry—The Evolving Landscape of Healthcare Coverage and Access in 2025,”1 the…
In a video interview with Pharma Commerce, Brad Stewart, BDO’s national life sciences co-leader, describes the challenges that tariffs may pose to reshoring manufacturing services in the life sciences industry. He highlights the complexity of supply chains in this sector, which are large, long, highly-regulated, and slow to change. Given…
In a video interview with Pharma Commerce, Jason C. Foster, CEO of Ori Biotech, describes how the current state of cell and gene therapies (CGTs) shows promising potential, particularly in curing cancer and rare diseases. These therapies are safe and effective, with evidence demonstrating their curative capability. However, their widespread…
It’s no secret that the pharmaceutical industry is facing a myriad of challenges and disruption, such as complex, costly, and lengthy new drug development; global regulatory hurdles; more start-ups entering the market every day, increasing competition; new technology and data solutions; lingering supply chain disruption, and more. Pharma leaders need…
March 14th 2025 Article Transitioning from manual temperature logs and reactive power outage management to a comprehensive cloud-based monitoring solution, Discount Drug Mart has revolutionized its approach to pharmacy operations and compliance. Adopting Sonicu’s advanced system, this Ohio-based retail pharmacy chain now benefits from seamless temperature monitoring and real-time power…
November 21st 2024 Article The pharmaceutical industry is evolving, and so are the strategies needed to connect with healthcare professionals. Closed-loop marketing (CLM) has become essential in delivering personalized, data-driven engagement that resonates with physicians and improves key outcomes, such as enhancing patient care, increasing
March 14th 2025 Article A regional hospital serving suburban Indianapolis, Hancock Regional Hospital faced a familiar challenge: disparate monitoring systems that taxed their staff and too many manual processes that drove inefficiencies. CEO Steve Long greenlit a solution: a consolidated temperature, environmental, and sound monitoring program that protected precious assets,…
Pre-Launch Prep for Emerging Biopharmas: Data First, Then the Rest Making early commercial data and analytics decisions for launch cen future-proof their data management. The Power of Three To Help Simplify the Business of Healthcare The healthcare industry faces unprecedented complexity impacting business stakeholder operations, from managing extensive documentation requirements…
In a video interview with Pharma Commerce, Jason C. Foster, CEO of Ori Biotech, describes how the current state of cell and gene therapies (CGTs) shows promising potential, particularly in curing cancer and rare diseases. These therapies are safe and effective, with evidence demonstrating their curative capability. However, their widespread…
Image Credit: Adobe Stock Images/WatermillStudio.com Cold Chain Technologies (CCT), a US-based provider of thermal packaging and digital monitoring solutions for the transportation of temperature-sensitive life sciences products, has acquired Global Cold Chain Solutions (GCCS), a provider of passive cold chain solutions based in Australia and India, for an undisclosed amount.1 GCCS is a…
In a video interview with Pharma Commerce, Brad Stewart, BDO’s national life sciences co-leader, describes the challenges that tariffs may pose to reshoring manufacturing services in the life sciences industry. He highlights the complexity of supply chains in this sector, which are large, long, highly-regulated, and slow to change. Given…
In a transaction officially set to close later this month, Syngene International Limited, a contract research, development, and manufacturing organization (CRDMO), acquired its first biologics site in the United States for $36.5 million.1 Equipped with multiple monoclonal antibody (mAbs) manufacturing lines, the state-of-the-art biologics facility in Baltimore was officially purchased by…
In a video interview with Pharma Commerce, Jason C. Foster, CEO of Ori Biotech, describes how the current state of cell and gene therapies (CGTs) shows promising potential, particularly in curing cancer and rare diseases. These therapies are safe and effective, with evidence demonstrating their curative capability. However, their widespread…
Image Credit: Adobe Stock Images/Mrzproducer.com PharmaCord LLC, a provider of patient services for the biopharmaceutical industry, and Mercalis, a life sciences commercialization partner, are merging to create a “total solutions provider” for the biopharma sector that is expected to offer solutions ranging from patient services to market access, in an…
Image Credit: Adobe Stock Images/Ketsara.com On Tuesday morning, as reported by AP,1 US President Trump announced that the original tax on steel and aluminum coming from Canada will double—increasing from 25% to 50%—due to the premier of Ontario, Doug Ford, implementing 25% tariffs on electricity that the nation sells to…
In a video interview with Pharma Commerce, Jason C. Foster, CEO of Ori Biotech, describes how the current state of cell and gene therapies (CGTs) shows promising potential, particularly in curing cancer and rare diseases. These therapies are safe and effective, with evidence demonstrating their curative capability. However, their widespread…
In a video interview with Pharma Commerce, Brad Stewart, BDO’s national life sciences co-leader, describes the challenges that tariffs may pose to reshoring manufacturing services in the life sciences industry. He highlights the complexity of supply chains in this sector, which are large, long, highly-regulated, and slow to change. Given…
The pharmaceutical manufacturing sector is experiencing a profound transformation driven by technological advancements, regulatory shifts, and market dynamics. Industry leaders are facing both unprecedented challenges and opportunities, making it essential to adopt new strategies to stay competitive. Innovations in manufacturing technologies, coupled with growing demands for personalized medicine and sustainability,…
Potential Tariff Impact on Availability & Accessibility of Medications for Telehealth Patients In this Pharmaceutical Executive Video Interview, Peter Ax, Founder & CEO of UpScriptHealth, discusses the impact of tariffs on the pharmaceutical industry, highlighting that tariffs will initially affect pharmaceutical companies, particularly those dealing with branded medications and generics.…
The Role Regulatory Agencies Should Play in the Battle Against Misinformation In this Pharmaceutical Executive video interview, Jen Butler, Chief Commercial Officer for Pleio, explores what kind of role regulatory agencies should play in the battle against misinformation. Developing Winning Supplemental Benefits Packages Facing a variety of financial pressures, health…
Healthcare’s Visual Future: Shaping Trust Through Design The six key design trends of 2025 redefine how healthcare brands can inspire trust and build lasting connections with their audiences. Direct Contracting: Not New, But New Interest Direct contracting is not a new concept: Cut out the insurers as middlemen and work…
In a video interview with Pharma Commerce, Tom Dorsett, CEO, RazorMetrics, describes how polypharmacy refers to the use of five or more medications by an individual, and it is becoming an increasingly prominent issue in the United States. Polypharmacy has been recognized for years but is growing more significant, especially…
Image Credit: Adobe Stock Images/MariusFaust.com A couple days following a tax that had gone into effect on various goods coming in from Canada and Mexico, President Trump has decided to postpone several of his previously announced1 25% tariffs on these trading partners after a concern for economic consequences—reported AP2—as he…
Image Credit: Adobe Stock Images/PinkEyes.com Astellas Pharma and YASKAWA Electric Corporation have signed a definitive agreement that officially commences a joint venture that revolves around the design of a cell therapy product manufacturing platform using Maholo, a dual-armed, humanoid robot created by the Robotic Biology Institute, a YASKAWA subsidiary.1 The…
In a video interview with Pharma Commerce, Tom Dorsett, CEO, RazorMetrics, describes how polypharmacy refers to the use of five or more medications by an individual, and it is becoming an increasingly prominent issue in the United States. Polypharmacy has been recognized for years but is growing more significant, especially…
PC: What are the legal implications of the latest tariffs—including the “reciprocal” variety—and what challenges do they present to the pharma supply chain? Lanton: Reciprocal tariffs could create significant disruptions in the supply chain and many commercial contracts. I don’t want to get overly technical, but many contracts include clauses…
Image Credit: Novo Nordisk Novo Nordisk, the manufacturer of Weggovy, is growing its offerings by creating NovoCare Pharmacy, a direct-to-patient (DTP) form of delivery that provides cash-paying patients with access to all dose strengths of Wegovy for $499 per month, at a lower cost.1 Intended for uninsured or eligible patients with commercial insurance…
In a video interview with Pharma Commerce, Geoffrey Joyce, PhD, director of health policy at the Leonard D. Schaeffer Center for Health Policy & Economics at the University of Southern California (USC, describes how the 10% tax on Chinese goods and a potential 25% tariff on pharmaceuticals could have notable…
It’s official—Trump’s tariffs on Canada and Mexico have now taken effect. In what the US president says is being tied to the threat posed by illegal aliens and drugs, including fentanyl, a 25% tariff has been implemented on imports from Canada and Mexico, with certain assets being taxed differently, such…
In a video interview with Pharma Commerce, Geoffrey Joyce, PhD, director of health policy at the Leonard D. Schaeffer Center for Health Policy & Economics at the University of Southern California (USC, describes how the 10% tax on Chinese goods and a potential 25% tariff on pharmaceuticals could have notable…
The landscape of healthcare provider (HCP) engagement has undergone a fundamental transformation. While traditional face-to-face interactions remain valuable, today’s HCPs interact across multiple channels throughout their day—from websites to social media platforms, professional forums, and digital portals. This evolution demands a sophisticated approach to engagement that meets HCPs where they…
Delivering Personalized Experiences at Scale: A Fresh Look at Customer Centricity Customer centricity. An overused buzzword in the life sciences industry. Yet an important goal. In an era of eroding rep access, fragmented channels and growing complexity in treatment decisions, building a customer-centric commercial operation is more difficult than ever. Combat…
In a video interview with Pharma Commerce, Geoffrey Joyce, PhD, director of health policy at the Leonard D. Schaeffer Center for Health Policy & Economics at the University of Southern California (USC, describes how the 10% tax on Chinese goods and a potential 25% tariff on pharmaceuticals could have notable…
Tracy Lopez uncovers the fundamentals pertaining to third-party logistics providers.
Image Credit: Adobe Stock Images/Natalia.com In early February, the news had originally broke that President Trump signed three executive orders that would enact tariffs on three key US trade partners: Canada, Mexico, and China.1 These taxes on imports, noted Trump at the time, stemmed from the threat posed by illegal…
As the pharmaceutical landscape evolves, ensuring market access should remain a top priority for industry stakeholders. As we look ahead to a year of expected advancements, several key trends will shape the landscape for manufacturers and key players. Here are four trends that will significantly impact market access strategies in…
Image Credit: Adobe Stock Images/StockMarketVisuals.com In an effort to increase its domestic medicine production across various therapeutic areas, Eli Lilly and Company will be constructing four new pharmaceutical manufacturing sites in the United States, representing financial commitments in the expansion space exceeding $50 billion since the start of 2020.1 The news comes…
In a video interview with Pharma Commerce, Geoffrey Joyce, PhD, director of health policy at the Leonard D. Schaeffer Center for Health Policy & Economics at the University of Southern California (USC, describes how the 10% tax on Chinese goods and a potential 25% tariff on pharmaceuticals could have notable…
In a video interview with Pharma Commerce, Geoffrey Joyce, PhD, director of health policy at the Leonard D. Schaeffer Center for Health Policy & Economics at the University of Southern California (USC, describes how the 10% tax on Chinese goods and a potential 25% tariff on pharmaceuticals could have notable…
Image Credit: Adobe Stock Images/AvectStock.com President Trump recently signed an executive order providing greater healthcare price transparency for patients.1 The order, says the Trump Administration, is expected to help lower healthcare prices, which will ultimately benefit patients and employers when it comes to seeking out deals on healthcare. Per Reuters,2…
Image Credit: Adobe Stock Images/TadaImages.com Eli Lilly and Company is unveiling its new 7.5 mg and 10 mg Zepbound (tirzepatide) single-dose vials, which will be available for $499 per month using its new Zepbound Self Pay Journey Program.1 The prices of the 2.5 mg and 5 mg vials—introduced last summer2—have also been…
In a video interview with Pharma Commerce, Tom Dorsett, CEO, RazorMetrics, describes how polypharmacy refers to the use of five or more medications by an individual, and it is becoming an increasingly prominent issue in the United States. Polypharmacy has been recognized for years but is growing more significant, especially…
Image Credit: Adobe Stock Images/Oporty786.com Selarsdi (ustekinumab-aekn) an injection for the treatment of psoriatic arthritis, plaque psoriasis, Crohn’s disease, ulcerative colitis, pediatric plaque psoriasis, and pediatric psoriatic arthritis that is also a biosimilar to Stelara (ustekinumab), is officially available in the United States.1 This represents under second biosimilar available in the…
In a video interview with Pharma Commerce, Tom Dorsett, CEO, RazorMetrics, describes how polypharmacy refers to the use of five or more medications by an individual, and it is becoming an increasingly prominent issue in the United States. Polypharmacy has been recognized for years but is growing more significant, especially…
2025 Pipeline Report: The Edge of Greatness? The biopharmaceutical industry has long been at the forefront of innovation. From the rise of precision medicine, to artificial intelligence technologies accelerating drug development, to the advent of small-molecule drugs, recent revolutions in pharmaceuticals are delivering better results for patients and more options…
Global Launch Strategies in the Current Political Climate James Foster, CEO and co-founder of Virax Biolabs, discusses how global launches are being impacted by changing geopolitical conditions. Pharmacists Help Patients Navigate Vaccine Schedules Many patients may struggle to understand the complex immunization schedules compiled by the CDC. How AI Can…